



CureVac's mRNA based Vaccine Candidate against SARS-CoV-2

Materials for discussion with EU APA group
July 27th, 2020

- STRICTLY CONFIDENTIAL -

Key discussion topics for today

In our last discussion, we concluded with the following actions, agreeing for CureVac to come back to the EU APA team on the following topics:

1. Update of ongoing [REDACTED]
2. How CureVac could [REDACTED]
3. Clarify the [REDACTED]
4. Clarify [REDACTED]

In addition, CureVac would like **clarity on timelines to get to an agreement about an EU APA**. Indeed, at the [REDACTED]

CureVac is e [REDACTED]

Early clarity and commitment

1. CureVac's SARS-CoV-2 Project: overview of the ongoing

-
-
-
-
-
-

Status of [redacted] results support doses [redacted]
[redacted]

2.

As a result, CureVac is now in a position to [REDACTED]
[REDACTED] - even at [REDACTED] to a level



450m europeans
300m vaccine regimens
600m doses

Clear priority populations

Health
Care
Workers

60+ years
old

Chronic
diseases

Manage supply risk

1. Across most promising vaccine modalities in clinical development:
 - Protein-based
 - Viral
 - mRNA
2. Across manufacturers: 200-400m doses each

3. Rationale for CureVac's proposed pricing

CureVac is

- R&D and manufacturing ramp-up commitment of

- Besides the

- CureVac recently

- CureVac is

Pricing reference points are emerging and CureVac's offer compares favourably despite large subsidies to other manufacturers

Based on initial Europe Regimen doses; in million€

Price: 
Cost of goods: 
Program cost: 
Public funding: 
Investments to build CureVac mRNA platform since 2000: 




CONFIDENTIAL

CureVac bearing the
development and
manufacturing
infrastructure risk

Pricing reference points are
emerging & [redacted]

4. Context for EU APA milestones: plan



Key Project Milestones of interest in context of EU APA

#	Milestone	Planned Date	Proposed upfront payment milestones
1			← Milestone 1
2			
3			
4			
5			
6			← Milestone 2
7			
8			
9			
10			← Milestone 3
11			
12			← Milestone 4

Release of EU APA upfront payment milestones

When results complete

- * Without the ongoing 15m€ Ph1 for which CureVac received CEPI funding
- ** 6 additional GMP/III manufacturing lines

CONFIDENTIAL

Next steps

CureVac is a cutting-edge but mid-sized European biotech without the deep pockets of big pharma, nor the massive US BARDA grants that some manufacturers have received

CureVac

CureVac needs



CureVac AG

Friedrich-Miescher-Strasse 15
72076 Tübingen, Germany
T +49 7071 9883-0

www.curevac.com

RNAActive®

RNArt®

RNAjuvant®

PureMessenger®

RNAntigen®

RNAntibody®

RNAimal®

CVCM®

The RNA Printer®